| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/26/2004 | US20040038929 Drugs against articular failure |
| 02/26/2004 | US20040038928 N-pyrazole A2A receptor agonists |
| 02/26/2004 | US20040038927 Methods of decreasing or preventing pain using spicamycin derivaties |
| 02/26/2004 | US20040038923 Comprises sialyltransferase inhibitors for decreasing cell-surface oligosaccharides; gene expression inhibition; side effect reduction |
| 02/26/2004 | US20040038921 Comprises double-stranded oligoribonucleic acid (dsRNA); hammerhead ribozymes |
| 02/26/2004 | US20040038916 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 02/26/2004 | US20040038914 Flavone/ flavanone derivatives for the systemic treatment and prophlaxis of uv-induced dermatoses |
| 02/26/2004 | US20040038913 Remedies for lung cancer |
| 02/26/2004 | US20040038911 Novel substituted sulfamate anticonvulsant derivatives |
| 02/26/2004 | US20040038910 Comprises L-arabinose and sucrose within food or beverage |
| 02/26/2004 | US20040038909 Food composition and weight loss method for treating obesity |
| 02/26/2004 | US20040038905 Anticancer agents |
| 02/26/2004 | US20040038904 Method of treating multiple sclerosis |
| 02/26/2004 | US20040038899 Polymer stabilized neuropeptides |
| 02/26/2004 | US20040038891 Contacting the tissue or organ with an effective amount of an apolipoprotein to treat, prevent or reduce ischemic reperfusion injury |
| 02/26/2004 | US20040038889 Fumaric acid amides |
| 02/26/2004 | US20040038884 Treatment of tinitus |
| 02/26/2004 | US20040038882 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 02/26/2004 | US20040038879 For therapy and prophylaxis of infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure |
| 02/26/2004 | US20040038874 Inhibiting the biochemical mediators of inflammation in a subject comprising administering to subject therapeutically effective dosage of inhibitor |
| 02/26/2004 | US20040038871 Attaching a linker to an amino group of the drug, the linker including an aldehyde or ketone carbonyl group, and forming an oxime by reaction of the carbonyl group with an O-alkylhydroxylamine derivative of the peptide |
| 02/26/2004 | US20040038870 Methods of drug delivery using sulphated chitinous polymers |
| 02/26/2004 | US20040038863 Therapy of growth failure in an individual, comprising administering to the individual an aromatase inhibitor |
| 02/26/2004 | US20040038859 Containing stabilizing agent comprising matrix metalloproteinase inhibitor |
| 02/26/2004 | US20040038858 Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours |
| 02/26/2004 | US20040038857 Treating the cell with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the cell, wherein the cell is a macrophage |
| 02/26/2004 | US20040038856 Treatment of fibroproliferative disorders using TGF-beta inhibitors |
| 02/26/2004 | US20040038854 Use of il-8 receptor antagonists in the treatment of virus infections |
| 02/26/2004 | US20040038416 Based on kinetics; quality control kits |
| 02/26/2004 | US20040038406 Nanoparticle delivery systems and methods of use thereof |
| 02/26/2004 | US20040038399 For preventing gene transcription/expression; for inducing nuclease stability, hybridization to complementary RNA sequences, permeability to oligonucleotides into cells, RNase cleavage, and blocking ribosome translocation |
| 02/26/2004 | US20040038364 Such as snake venom proteases; anticoagulants |
| 02/26/2004 | US20040038339 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 02/26/2004 | US20040038313 Inhibitors of agonist-specific desensitization |
| 02/26/2004 | US20040038303 Comprises use of small particle with appropriate hydrophilic-lipophilic-balance value to deliver anticarcinogenic agents to cells and/or tissues; drug screening |
| 02/26/2004 | US20040038297 Masp-2,a complement-fixing enzyme, and uses for it |
| 02/26/2004 | US20040038281 Isolated ductal fluid sample |
| 02/26/2004 | US20040038278 Methods and compositions relating to gene silencing |
| 02/26/2004 | US20040038275 Human frezzled-like protein |
| 02/26/2004 | US20040038274 Gapped 2' modified oligonucleotides |
| 02/26/2004 | US20040038271 Novel C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| 02/26/2004 | US20040038265 Using low density lipoprotein related proteins (LRP) to diagnose, treat and prevent paget's, osteoporosis, cirrhosis and rickets |
| 02/26/2004 | US20040038247 Expression vector comprised of regulatory sequences for lymphocyte specific expression of heterologous polypeptides |
| 02/26/2004 | US20040038239 A reporter system that transports GPI(glycosyl-phosphatidyl inositol-anchored proteins to the cell wall, was constructed and a gene that inhibit the transportaton of above protein is identified and a antifungal compound is discovered |
| 02/26/2004 | US20040038236 Mutation associated with epilepsy |
| 02/26/2004 | US20040038209 Comprises nucleotide sequences coding beta -carotene dioxygenase which cleaves beta carotene and produces vitamin a aldehyde; improving nutritional value of plants, microorganisms and animal feeds |
| 02/26/2004 | US20040038204 Replacing worn wear strip associated with viral and nonviral gene delivery systems; gene therapy |
| 02/26/2004 | US20040038203 Comprises nucleotide sequences coding yaba monkey tumor viral protein for treatment and prevention of autoimmune diseases |
| 02/26/2004 | US20040037908 Dissolving a Simmondsins extract (Jojoba oil) in a solvent, adding a carbonaceous adsorbent, e.g., activated carbon; separating the adsorbent to obtain purified liquid extract; drying; anorexigenic agent; animal feed; organoleptic; |
| 02/26/2004 | US20040037907 Parenteral pimaricin as treatment of systemic infections |
| 02/26/2004 | US20040037904 Ready-to-use aqueous composition of a water-diluted vegetable oil, preferably soybean oil, saponified almost 100% by a Group 1A hydroxide, preferably potassium hydroxide; nontoxic; biodegradation; emulsifier-free; pesticides; antifertility |
| 02/26/2004 | US20040037903 A dietary supplement of resveratrol and turmeric extract; nontoxic as an antiinflammatory agent and analgesic; side effect reduction; cartiledge protection; oxidation resistance |
| 02/26/2004 | US20040037902 Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species |
| 02/26/2004 | US20040037897 Treatment of drug resistant organisms |
| 02/26/2004 | US20040037896 Intravenous injection of lignocaine (lidocaine) or a salt, ester or metabolite for use in initiating the natural capacity to regenerate collateral blood vessels; cerebral arterial occlusions; artherosclerosis; angina pectoris |
| 02/26/2004 | US20040037895 Methods of treating involuntary facial spasms and facial wrinkles |
| 02/26/2004 | US20040037892 Oral administration of a mixture of octadeca-9,11-dienoic acid (CLA), docosahexaenoic acid, vitamins E, C, B6 and B12, folic acid and calcium; dietary supplements; cardiovascular disorders; anticholesterol and hypotensive agents |
| 02/26/2004 | US20040037888 Administering intrarectally or to anorectal region aqueous gel composition containing drug effective in such treatment and carrier comprising water soluble cellulose derivative gelling agent, propylene glycol, water |
| 02/26/2004 | US20040037886 Drug eluting coatings for medical implants |
| 02/26/2004 | US20040037884 Novel dosage forms of risedronate |
| 02/26/2004 | US20040037883 Controlled release dosage forms |
| 02/26/2004 | US20040037882 Opioid agonist in a fast dispersing dosage form |
| 02/26/2004 | US20040037881 Administering composition and dosage form comprising oxybutynin alone/or accompanied by another drug indicated for therapy |
| 02/26/2004 | US20040037880 Extended release formulation of divalproex sodium |
| 02/26/2004 | US20040037879 Oral controlled release forms useful for reducing or preventing nicotine cravings |
| 02/26/2004 | US20040037876 Use or r-arylpropionic acids for producing medicaments for treating illnesses with a rheumatic nature |
| 02/26/2004 | US20040037875 Composition for treatment of inflammatory disorders |
| 02/26/2004 | US20040037874 Delivery of nucleic acid-like compounds |
| 02/26/2004 | US20040037873 Norethindrone sustained release formulations and methods associated therewith |
| 02/26/2004 | US20040037872 Active substance-containing adhesive patch comprising diclofenac or a topically acceptable salt thereof; patch composed of outer impermeable backing layer, matrix layer comprising active substance, removable protective layer |
| 02/26/2004 | US20040037860 Topical for cellulite reduction |
| 02/26/2004 | US20040037857 Anti-pollution composition based on anthocyanic pigments |
| 02/26/2004 | US20040037836 Comprises nitroglycerin; for preventing adverse effects associated with medical device implantation; for inhibiting platelet deposition; angiotensin converting enzyme inhibitors |
| 02/26/2004 | US20040037829 For immunoregulation and/or treatment of inflammation; muteins |
| 02/26/2004 | US20040037828 Methods and pharmaceutical compositions for healing wounds |
| 02/26/2004 | US20040037824 Epidermal growth factors (ErbB2); gene expression inhibition; anticancer agents |
| 02/26/2004 | US20040037823 Epidermal growth factors (ErbB2); comprises doxorubicin; gene expression inhibition; anticancer agents |
| 02/26/2004 | US20040037806 Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| 02/26/2004 | US20040037804 Methods combining glucocorticoids and cytokines for the treatment of inflammatory disorders are disclosed. |
| 02/26/2004 | US20040037790 An oral composition comprising: an oil extract of mastic; and an antiphlogistic. A dentrifice comprising the oral composition according to claim 1 and a gargle |
| 02/26/2004 | US20040037785 Method of making particles for use in a pharmaceutical composition |
| 02/26/2004 | US20040037784 Particulate (2S)-3-(4-(((4-(aminocarbonyl)-1-piperidinyl) carbonyl)oxy)phenyl)-2-(((2S)-4-methyl-2-((2-(2-methylphenoxy) acetyl)amino)pentanoyl)amino) propanoic acid or a salt or solvate thereof and one or more suitable excipients for |
| 02/26/2004 | US20040037783 Pharmaceutical formulation of fluticasone propionate |
| 02/26/2004 | US20040037778 Iodinated and/or brominated derivatives of aromatic dihydroxy monomers are prepared and polymerized to form radio-opaque polymers. The monomers may also be copolymerized with other dihydroxy monomers. The iodinated and brominated aromatic |
| 02/26/2004 | US20040037773 Method for detecting abnormal tissue using enhanced radiopharmaceutical uptake |
| 02/26/2004 | US20040037022 Aminoalcohol derivatives |
| 02/26/2004 | DE3921022B4 Mitomycinphosphatderivat und pharmazeutisches Mittel, das diese Verbindung als Antitumorwirkstoff enthält Mitomycinphosphatderivat and pharmaceutical agent containing this compound as an antitumor agent |
| 02/26/2004 | DE20318634U1 Topical compositions for preventing or treating rhinitis, comprising sympathomimetic agent with vasoconstrictive and/or mucosal swelling reducing action and glycosaminoglycan to reduce side-effects |
| 02/26/2004 | DE20318413U1 Actives combination for use as a cosmetic or dermatological composition contains creatine and/or creatinine together with phenoxyethanol and optionally also glycerol |
| 02/26/2004 | DE20315397U1 Topical preparations for treating summer eczema in horses, comprising salicylic acid compound, citronellal, tea tree oil, oil of cloves and thyme oil |
| 02/26/2004 | DE20220604U1 Zusammensetzung, enthaltend feine Partikel zur Langzeitfreisetzung für schnell in der Mundhöhle zerfallende Tabletten Composition containing fine particles for sustained release of rapidly disintegrating in the oral cavity tablets |
| 02/26/2004 | DE10329926A1 Combination medicament, useful e.g. as anesthetic, sedative or hypnotic, comprising xenon (or gas mixture containing xenon) and dexmedetomidine |
| 02/26/2004 | DE10316660A1 New diarylacetic acid quaternized azabicycloheptyl esters, useful e.g. for treating asthma, chronic obstructive pulmonary disease, arrhythmia or menstrual disorders, are anticholinergic agents |
| 02/26/2004 | DE10309368A1 Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase Pharmaceutical preparation containing RNA as a cofactor of hemostasis |
| 02/26/2004 | DE10237739A1 Inhalable medicament for treating inflammatory or obstructive respiratory diseases, containing synergistic combination of tropane derivative anticholinergic agent, corticosteroid and beta-mimetic agent |
| 02/26/2004 | DE10237232A1 Aqueous solution for inhalation, useful for treating respiratory disease, contains anticholinergic tricyclo-oxa-aza-nonane derivative and requires no propellant |
| 02/26/2004 | DE10232020A1 Neurorezeptoraktive Heteroarencarboxamide Neuroreceptor Active Heteroarencarboxamide |
| 02/26/2004 | DE10228078B3 Composition for coating implants, e.g. stents, to inhibit smooth muscle cell proliferation and restenosis, comprising mixture of low-molecular or oligomeric estrogen ester and estrogen |
| 02/26/2004 | DE10145814A1 Verwendung einer Genveränderung im Gen GNB3 kodierend für die β3-Untereinheit menschlicher G-Proteine Use of a gene in the gene GNB3 encoding the β3 subunit of human G-proteins |
| 02/26/2004 | CA2835747A1 Compositions comprising dietary fat complexer and methods for their use |